Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Treasury Shares (2022 - 2025)

Historic Treasury Shares for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $2.6 million.

  • Orchestra BioMed Holdings' Treasury Shares rose 1101.92% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 1101.92%. This contributed to the annual value of $2.1 million for FY2024, which is 2312.33% up from last year.
  • According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Treasury Shares is $2.6 million, which was up 1101.92% from $2.2 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' Treasury Shares' 5-year high stood at $3.9 million during Q1 2023, with a 5-year trough of $49237.0 in Q2 2023.
  • Its 4-year average for Treasury Shares is $1.9 million, with a median of $2.0 million in 2024.
  • The largest annual percentage gain for Orchestra BioMed Holdings' Treasury Shares in the last 5 years was 492830.39% (2024), contrasted with its biggest fall of 5695.15% (2024).
  • Orchestra BioMed Holdings' Treasury Shares (Quarter) stood at $158589.0 in 2022, then surged by 972.72% to $1.7 million in 2023, then rose by 23.12% to $2.1 million in 2024, then increased by 25.42% to $2.6 million in 2025.
  • Its Treasury Shares was $2.6 million in Q3 2025, compared to $2.2 million in Q2 2025 and $1.9 million in Q1 2025.